Strategic Investments and Adjusted Gross Margin Report slide image

Strategic Investments and Adjusted Gross Margin Report

BAT INVESTMENTS IN ORGANIGRAM • March 2021 $221 million strategic investment from subsidiary of BAT for 19.9% equity interest in Organigram • Product Development Collaboration (PDC) with formation of a Center of Excellence (COE) at our Moncton campus Focused on developing the next generation of cannabis products, IP and technologies November 2023 - $124.6 million follow-on investment from subsidiary of BAT in three equal tranches between January 2024 and February 2025 for: 45.0% economic interest in Organigram (accreting to maximum • . of 49.0%), voting interest capped at 30.0% with maximum 30.0% Board rights Private placement at C $3.2203/share2 yielding $124.6 million Organigram to create a Strategic Investment Pool named Jupiter, to be funded with C$83.1 million over the course of the three tranches of the investment Jupiter will target investments in emerging cannabis opportunities that enable Organigram to apply industry-leading capabilities to new markets, thus expanding its global footprint • $41.5 million proceeds for general corporate purposes First $41.5 million tranche closed in January 2024 1. Calculated on a non-diluted basis. 2. On the last trading day pre-announcement (November 3, 2023) of the transaction. Organigram shares closed at C$1.59/share on the Toronto Stock Exchange. ORGANIGRAM BAT ORGANIGRAM 9
View entire presentation